Patents by Inventor Robert Graziano

Robert Graziano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against Clostridium difficile toxins and uses thereof
    Publication number: 20050287150
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Application
    Filed: February 4, 2005
    Publication date: December 29, 2005
    Applicants: UNIVERSITY OF MASSACHUSETTS, MEDAREX, INC.
    Inventors: Donna Ambrosino, Gregory Babcock, Teresa Broering, Robert Graziano, Hector Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William Thomas, Hui-Fen Zhang
  • Human anti-IRTA-5 antibodies
    Publication number: 20050266008
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-5, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
    Type: Application
    Filed: March 28, 2005
    Publication date: December 1, 2005
    Applicant: Medarex, Inc.
    Inventors: Robert Graziano, Josephine Cardarelli, Thomas Kempe, Beth Cutter, Mohan Srinivasan
  • Cells expressing anti-Fc receptor binding components
    Publication number: 20050142120
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Application
    Filed: January 23, 2004
    Publication date: June 30, 2005
    Inventors: Tibor Keler, Joel Goldstein, Robert Graziano, Yashwant Deo
  • Cells expressing anti-Fc receptor binding components
    Patent number: 6682928
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: January 27, 2004
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Robert Graziano, Yashwant M. Deo
  • Human monoclonal antibodies against CD30
    Publication number: 20040006215
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: January 7, 2003
    Publication date: January 8, 2004
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • CELLS EXPRESSING ANTI-FC RECEPTOR BINDING COMPONENTS
    Publication number: 20030039641
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Application
    Filed: December 2, 1998
    Publication date: February 27, 2003
    Inventors: TIBOR KELER, JOEL GOLDSTEIN, ROBERT GRAZIANO, YASHWANT M. DEO
  • Therapeutic compounds comprised of anti-Fc receptor antibodies
    Patent number: 6410690
    Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 25, 2002
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
  • Therapeutic compounds comprised of anti-Fc receptor antibodies
    Patent number: 6395272
    Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: May 28, 2002
    Assignee: Mederex, Inc.
    Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
  • Therapeutic compounds comprised of anti-FC receptor binding agents
    Patent number: 6365161
    Abstract: Multispecific molecules which target immune cells are disclosed. The molecules are “multispecific” because they bind to multiple (two or more), distinct targets, one of which is a molecule on the surface of an immune cell. Multispecific molecules of the invention include molecules comprised of at least one portion which binds to a molecule on an effector cell, such as an Fc receptor, and at least one portion (e.g., two, three, four or more portions) which binds to a different target, such as an antigen on a tumor cell or a pathogen. Multispecific molecules of the invention also include antigen “multimer complexes” comprised of multiple (i.e., two or more) portions which bind to a molecule on an antigen presenting cell (APC), such as an Fc receptor, linked to one or more antigens. These multimer complexes target antigens, such as self-antigens, to APCs to induce and/or enhance internalization (endocytosis), processing and/or presentation of the antigen by the APC.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: April 2, 2002
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Tibor Keler
  • THERAPEUTIC COMPOUNDS COMPRISED OF ANTI-FC RECEPTOR ANTIBODIES
    Publication number: 20020032312
    Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
    Type: Application
    Filed: June 7, 1995
    Publication date: March 14, 2002
    Applicant: MEDAREX, INC.
    Inventors: YASHWANT M. DEO, JOEL GOLDSTEIN, ROBERT GRAZIANO, CHEZIAN SOMASUNDARAM
  • Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies
    Patent number: 6303755
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: October 16, 2001
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Therapeutic multispecific compounds comprised of anti-Fcalpha receptor antibodies
    Publication number: 20010014328
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.
    Type: Application
    Filed: January 26, 2001
    Publication date: August 16, 2001
    Applicant: Mederax, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Therapeutic compounds comprised of anti-Fc receptor antibodies
    Patent number: 6270765
    Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: August 7, 2001
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
  • Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies
    Patent number: 6193966
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: February 27, 2001
    Assignee: Mederax, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies
    Patent number: 5922845
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies and methods of use are provided.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: July 13, 1999
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Therapeutic compounds comprised of anti-Fc receptor antibodies
    Patent number: 5837243
    Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: November 17, 1998
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram